Chitosan Oleate Coated PLGA Nanoparticles as siRNA Drug Delivery System.
PLGA nanoparticles
chitosan oleate
nucleic acid delivery
polyplexes
siRNA
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Oct 2021
17 Oct 2021
Historique:
received:
03
08
2021
revised:
08
10
2021
accepted:
14
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Oligonucleotide therapeutics such as miRNAs and siRNAs represent a class of molecules developed to modulate gene expression by interfering with ribonucleic acids (RNAs) and protein synthesis. These molecules are characterized by strong instability and easy degradation due to nuclease enzymes. To avoid these drawbacks and ensure efficient delivery to target cells, viral and non-viral vectors are the two main approaches currently employed. Viral vectors are one of the major vehicles in gene therapy; however, the potent immunogenicity and the insertional mutagenesis is a potential issue for the patient. Non-viral vectors, such as polymeric nanocarriers, provide a safer and more efficient delivery of RNA-interfering molecules. The aim of this work is to employ PLGA core nanoparticles shell-coated with chitosan oleate as siRNA carriers. An siRNA targeted on HIV-1, directed against the viral Tat/Rev transcripts was employed as a model. The ionic interaction between the oligonucleotide's moieties, negatively charged, and the positive surface charges of the chitosan shell was exploited to associate siRNA and nanoparticles. Non-covalent bonds can protect siRNA from nuclease degradation and guarantee a good cell internalization and a fast release of the siRNA into the cytosolic portion, allowing its easy activation.
Identifiants
pubmed: 34684009
pii: pharmaceutics13101716
doi: 10.3390/pharmaceutics13101716
pmc: PMC8539707
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R21 AI161075
Pays : United States
Références
Future Sci OA. 2017 Sep 14;4(1):FSO225
pubmed: 29255618
Nucleic Acids Res. 2005 Jul 26;33(13):4140-56
pubmed: 16049023
Front Physiol. 2021 Jul 01;12:668330
pubmed: 34276398
J Control Release. 2020 Sep 10;325:249-275
pubmed: 32634464
Front Bioeng Biotechnol. 2014 Dec 11;2:65
pubmed: 25566532
Gene Ther. 2006 Mar;13(6):464-77
pubmed: 16341059
J Nanosci Nanotechnol. 2014 Jan;14(1):564-76
pubmed: 24730283
AAPS PharmSciTech. 2010 Mar;11(1):64-72
pubmed: 20058108
Mar Drugs. 2018 Nov 15;16(11):
pubmed: 30445668
Philos Trans R Soc Lond B Biol Sci. 2009 Jan 12;364(1513):99-115
pubmed: 18926973
Int J Biol Macromol. 2016 Oct;91:615-22
pubmed: 27196368
Nat Rev Cancer. 2011 Jan;11(1):59-67
pubmed: 21160526
Trends Pharmacol Sci. 2021 Jun;42(6):448-460
pubmed: 33875229
Nature. 2009 Jan 22;457(7228):426-33
pubmed: 19158789
Molecules. 2019 Jul 15;24(14):
pubmed: 31311176
Biotechnol J. 2011 Sep;6(9):1130-46
pubmed: 21744502
Mar Drugs. 2019 Jun 25;17(6):
pubmed: 31242678
Nano Lett. 2019 Apr 10;19(4):2272-2279
pubmed: 30829039
Neurosci Lett. 2011 Apr 20;494(1):14-8
pubmed: 21352894
Nucleosides Nucleotides Nucleic Acids. 2020;39(1-3):292-309
pubmed: 31509065
Bioconjug Chem. 2011 Aug 17;22(8):1690-9
pubmed: 21736371
Nano Lett. 2010 Oct 13;10(10):3933-9
pubmed: 20795625
Mol Pharm. 2009 May-Jun;6(3):659-68
pubmed: 19267452
Smart Mater Med. 2020;1:10-19
pubmed: 34553138
J Control Release. 2006 Oct 10;115(2):216-25
pubmed: 16959358
Drug Deliv Transl Res. 2020 Aug;10(4):962-974
pubmed: 32170657
Nat Nanotechnol. 2007 Aug;2(8):469-78
pubmed: 18654343
Curr Atheroscler Rep. 2021 Sep 1;23(11):69
pubmed: 34468873
Int J Nanomedicine. 2012;7:3637-57
pubmed: 22915840
Nature. 2001 May 24;411(6836):494-8
pubmed: 11373684
Biomacromolecules. 2005 Nov-Dec;6(6):3357-66
pubmed: 16283766
Eur J Pharm Biopharm. 2014 Nov;88(3):643-50
pubmed: 25128852
Biomaterials. 2018 Nov;184:1-9
pubmed: 30195140
Eur J Pharm Biopharm. 2015 Jun;93:52-79
pubmed: 25813885
Nanomedicine (Lond). 2019 Mar;14(5):511-514
pubmed: 30806159
J Biomed Mater Res A. 2013 Oct;101(10):2957-66
pubmed: 23613460
Biomacromolecules. 2018 Jan 8;19(1):112-131
pubmed: 29211954
J Neural Transm Suppl. 2007;(72):43-9
pubmed: 17982877
J Intern Med. 2010 Jan;267(1):9-21
pubmed: 20059641
Biotechniques. 2006 Apr;Suppl:25-9
pubmed: 16629384
J Gene Med. 2019 Jul;21(7):e3097
pubmed: 31069898
Nat Rev Genet. 2007 Mar;8(3):173-84
pubmed: 17304245
Theranostics. 2018 Feb 7;8(6):1575-1590
pubmed: 29556342
Mol Pharm. 2009 May-Jun;6(3):651-8
pubmed: 19115957
Adv Drug Deliv Rev. 2019 Apr;144:133-147
pubmed: 31102606
Curr Pharm Des. 2015;21(31):4529-40
pubmed: 26486140
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Eur J Pharm Biopharm. 2014 May;87(1):101-6
pubmed: 24384070
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):12996-3001
pubmed: 21784981
Colloids Surf B Biointerfaces. 2017 Apr 1;152:385-392
pubmed: 28152462
Oral Dis. 2000 Sep;6(5):303-9
pubmed: 11002413
Nat Biotechnol. 2005 Feb;23(2):222-6
pubmed: 15619617
Int J Biol Macromol. 2019 May 15;129:305-315
pubmed: 30738164
Bioconjug Chem. 2013 Apr 17;24(4):487-519
pubmed: 23461774
Sci Rep. 2019 Nov 1;9(1):15825
pubmed: 31676815
Mol Ther. 2008 Aug;16(8):1481-9
pubmed: 18461053
Mar Drugs. 2019 Sep 01;17(9):
pubmed: 31480614
Chem Commun (Camb). 2019 Apr 25;55(35):5139-5142
pubmed: 30977478
J Pharm Sci. 2011 Apr;100(4):1488-502
pubmed: 24081472
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
J Control Release. 2009 Oct 15;139(2):146-52
pubmed: 19567259
Methods Mol Biol. 2019;1937:125-134
pubmed: 30706393
Nat Rev Drug Discov. 2017 Mar;16(3):181-202
pubmed: 27807347
Adv Healthc Mater. 2017 Jan;6(2):
pubmed: 27886461
Food Funct. 2021 Sep 7;12(17):7909-7922
pubmed: 34250536
J Control Release. 2013 Apr 10;167(1):29-39
pubmed: 23298612